The scientific organisers Ardeschir Ghofrani, Stuart Rich and John Newman warmly invite you to attend our 4th Annual Drug Discovery and Development Symposium being held this summer in Berlin, on behalf of the PVRI.
This year, the Annual Drug Discovery and Development for Pulmonary Hypertension Symposium will be held in Berlin. The meeting brings leading scientists in the fields of pulmonary vascular disease, right heart failure, and clinical trial designs together with the pharmaceutical industry and regulatory authorities to help identify the most promising treatments for future development. The faculty this year includes world renowned academic experts and members of the EMA.
For each meeting, we assemble a faculty with exceptional achievements and expertise, and choose topics in areas that will influence the development of therapies immediately. Each topic will be critically reviewed by an expert panel, and open dialogue will allow your voice to be heard.
This symposium serves as a unique forum for stakeholders interested in treatment of pulmonary vascular diseases for the sharing of cutting-edge science with the input of international thought leaders.
- For researchers involved in the treatment of pulmonary hypertension this meeting should stimulate new ideas and approaches.
- For the pharmaceutical and biotechnology industries that have an interest in pulmonary vascular diseases, right heart failure or orphan diseases, it is a meeting that should not be missed.
The meeting by design allows for opportunities for interaction among colleagues during meeting and at the evening reception.
Each registree will receive a private link with the opportunity to book at the conference hotel with reduced rates and additional gratuities in an email shortly after registering.
The event will take place on 10 and 11 July 2017.
If you are part of government or regulatory institution and would like to attend this event, please email email@example.com and we will be in touch with registration details.
Through worldwide collaboration, we can begin to answer the question of a global disease.